DECISION Trial
Cross-source consensus on DECISION Trial from 1 sources and 5 claims.
1 sources · 5 claims
Other
Highlighted claims
- DECISION was a double-blind randomized placebo-controlled trial conducted at 43 Dutch sites. — Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial
- Patients were randomized equally to low-dose digoxin or placebo. — Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial
- The primary analysis included 1,001 patients after one randomized patient was excluded before unblinding. — Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial
- The median follow-up was 36.5 months. — Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial
- No patients were lost to follow-up and no unblinding events occurred. — Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial